anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A 1,3-oxazolidin-2-one derivative expressed by formula I (R1, R2 and R3 are H, lower alkyl, lower alkoxy or halogen; n is 4, 5 or 6). EXAMPLE:(4RS,5SR)-4,5-Diphenyl-3-(3-piperidinopropyl)-1, 3-oxazolidin-2-one. USE:Useful as a medicine having improved central nervous system muscular relaxing action, i.e. rigidity remitting action on anemic decerebrate rigidity. PREPARATION:For example, a compound expressed by formula II is reacted with a compound expressed by formula III (X is eliminative group, e.g. halogen, tosyloxy or acetoxy, etc.) in the presence of a weak base, e.g. potassium carbonate or sodium carbonate, at 50 deg.C- refluxing temperature to afford the aimed compound expressed by formula I. Preferably, the compound expressed by formula III is used in a molar amount of 1-2 times based on the compound expressed by formula II, and the weak base is used in a molar amount of twice of more based on the compound expressed by formula II.
This is a multi-site trial (12 patients in each site). The investigators are recruiting 24 patients who will be randomized into either a spinning class, yoga class, dance class, or no exercise intervention. Classes will be conducted twice a week for 6 weeks total at times convenient for the patients. Patients will also be asked to complete questionnaires after exercise classes to see if the exercise intervention improves measures of fatigue, anxiety, and depression - and what exercise intervention may be superior. All participants will be asked to complete questionnaires each week and will be asked to wear a "Microsoft exercise band" during the course of the study. Use of the exercise band is optional.
Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
Dose schedules were calculated to maintain similar BED for late normal tissue injury (α/β= 3.0 Gy), with an increased BED for PC (α/β= 1.5Gy). Patients be treated with 12 fractions. A total of 6 patients will be treated at the dose that is determined to be Maximum Tolerated Dose.
Any patient aged 0-100 with MPS type I, type III, type IV and type VI. Type VII MPS patients may also be eligible.
BACKGROUND: The first studies on patients with forkhead-box protein P1 (FOXP1) syndrome reported associated global neurodevelopmental delay, autism symptomatology, dysmorphic features and cardiac and urogenital malformations. The aim of this study was to assess the prevalence of congenital abnormalities in an unbiased cohort of patients with FOXP1 syndrome and to document rare complications.
METHODS: Patients with FOXP1 syndrome were included, mostly diagnosed via whole-exome sequencing for neurodevelopmental delay. A parent-report questionnaire was used to assess medical signs and symptoms, including questions about features rated as most burdensome by patients and their family.
RESULTS: Forty individuals were included, 20 females and 20 males. The mean age at assessment was 13.2 years (median 8.5 years; range 2-54 years; ≥18 years n = 7). Seven adults were included. All patients had developmental problems, including cognitive, communication, social-emotional and motor delays. The most prevalent medical signs and symptoms include delayed bladder control, sleeping problems, hypermetropia, strabismus, sacral dimple, undescended testes, abnormal muscle tone and airway infections. The most burdensome complaints for patients with FOXP1 syndrome, as perceived by parents, include intellectual disability, impaired communication, behaviour problems, lack of age-appropriate self-reliance, attention problems and anxiety. According to parents, patients have quite similar reported symptoms, although incontinence, obsessions and a complex sensory profile have a higher ranking.
CONCLUSION: The results of this study may be used to further guide medical management and identify patient priorities for future research targeted on those features of FOXP1 syndrome that most impair quality of life of patients and their families.
Age-related neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by deposits of protein aggregates, or amyloid, in various regions of the brain. Historically, aggregation of a single protein was observed to be correlated with these different pathologies: tau in AD and α-synuclein (αS) in PD. However, there is increasing evidence that the pathologies of these two diseases overlap, and the individual proteins may even promote each other's aggregation. Both tau and αS are intrinsically disordered proteins (IDPs), lacking stable secondary and tertiary structure under physiological conditions. In this study we used a combination of biochemical and biophysical techniques to interrogate the interaction of tau with both soluble and fibrillar αS. Fluorescence correlation spectroscopy (FCS) was used to assess the interactions of specific domains of fluorescently labeled tau with full length and C-terminally truncated αS in both monomer and fibrillar forms. We found that full-length tau as well as individual tau domains interact with monomer αS weakly, but this interaction is much more pronounced with αS aggregates. αS aggregates also mildly slow the rate of tau aggregation, although not the final degree of aggregation. Our findings suggest that co-occurrence of tau and αS in disease are more likely to occur through monomer-fiber binding interactions, rather than monomer-monomer or co-aggregation.
Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
[Problems]To provide a method for producing regenerated T cells via iPS cells into which TCRs isolated from tumor tissue-infiltrating CD106-positive T cells have been introduced.[Solutions]Provided is a method for producing regenerated T cells via iPS cells, comprising: 1. A step for preparing cDNAs respectively encoding a TCR α chain and a TCR β chain from individual cells in a CD106-positive T cell population obtained from subjects and having reactivity with a tumor-related antigen; 2. A step for reprogramming peripheral blood mononuclear cells which are obtained from the subjects and from which B cells and T cells have been removed or T cells into iPS cells, and selecting iPS cell clones having high efficiency of differentiation into T cells from the obtained iPS cells; 3. A step for introducing the cDNAs into the iPS cell clones, hematopoietic stem cells differentiated from the iPS cell clones, immature T cells differentiated from the hematopoietic stem cells, or mature T cells differentiated from the immature T cells; and 4. A step for performing the differentiation of the iPS cell clones having the cDNAs introduced therein, the hematopoietic stem cells or the immature T cells which have been obtained in step 3 into mature T cells and the proliferation of the mature T cells.
NEW MATERIAL:A compound which has activity to differentiate and grow a mouse leukemia cell into a normal cell, an amino acid sequence shown by the formula and the following physical and chemical properties. Molecular weight: 16+ or -1kd[SDS-electrophoresis method in the presence of mercaptoethanol(ME)] and 25+ or -1kd (the same method in the absence of ME]. Isoelectric point: pI 6.3+ or -0.2 (chromatofocusing method) and pI 7.3 (esoelectric point electrophoresis method. pH Stability: stable at pH2.0-10.0. Thermal stability: stable under heating at 65 deg.C for 50min. USE:A remedy for human leukemia and anemia. PREPARATION:For example, a human malignant leukemia cell is suspended in a medium, put in a microtitre plate, cultivated at 37 deg.C in the presence of a differentiation-inducing substance such as phorbol ester (TPA), etc., having an action to produce BUF-3 when brought into contact with a human leukemia cell and a product is separated from the culture mixture to give a compound shown by the formula.
The invention concerns a radiopaque, non-biodegradabie, water-insoluble iodinated benzyl ether of polyvinyl alcohol) consisting of a PVA having covalentiy grafted thereon iodinated benzyl groups comprising 1 - 4 iodine atoms per benzyl group, a process for preparing the same comprising reacting a 0 - 100 % hydrolyzed PVA with a iodinated benzyl derivative comprising 1 - 4 iodine atoms per benzyl group in a polar aprotic solvent in the presence of a base in anhydrous conditions. Said iodo-benzylether-PVA is particularly useful as embolic agent in an injectable embolizing composition. The invention also concerns an injectable embolizing composition comprising said iodo-benzylether-PVA and capable of forming a cohesive mass upon contact with a body fluid by precipitation of the iodo- benzylether-PVA. Said injectable embolizing composition is particularly useful for forming in-situ a cohesive mass in a blood vessel or into a tumor. The invention further concerns a coating composition containing said iodo-benzylether-PVA and capable of forming a radiopaque coating on a medical device. The invention further concerns particles formed of said iodo-benzylether-PVA.
After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
The aims of this study is to explore the associations between spiritual well-being, self-compassion, physical symptom distress and demoralization in hemodialysis patients.

A cross-sectional correlation design will be used. We use convenient sample to recruit hemodialysis patients in a regional teaching hospital in the southern Taiwan. The research data is collected with a pact of self-administrated questionnaire including Chinese version of the Demoralization Scale , FACITsp-12 Scale, Self-Compassion Scale, and Physical Symptom Distress Scale. SPSS statistical software will be used to data analysis. Analysis methods included descriptive and inferential statistics. Finally, multiple linear regression will be used to test the predictors of demoralization. The research results will offer health providers to identify symptoms related to demoralization earlier and provide appropriate care to patients to adapt the long treatment process and improve their quality of life
BACKGROUND: Acupuncture, a traditional Chinese medical treatment, has been gaining popularity over the years. However, it also presents certain risks. We report a case of a patient who discovered a foreign body in their lung several years after undergoing acupuncture.
CASE PRESENTATION: A middle-aged woman presented to our hospital with chest pain. An X-ray revealed a needle-like foreign body in the middle lobe of her right lung. The patient had previously undergone acupuncture treatment for local pain in her lower back and lower extremities many years prior. Based on the imaging findings and her medical history, we hypothesized that the foreign body in her lung was a result of a dislodged acupuncture needle. Through preoperative 3-dimensional reconstruction and indocyanine green localization, we were able to locate the foreign body in the lateral segment of the right middle lobe. We successfully removed the foreign body via wedge resection, and the patient made a smooth recovery post-surgery.
CONCLUSION: Acupuncturists and surgeons should remain vigilant about the potential risks associated with acupuncture.
Heart failure (HF) can damage various organs, including the liver, a phenomenon known as "cardiohepatic syndrome." The latter is characterized by liver congestion and hepatic artery hypoperfusion, which can lead to liver damage. In this study, we aimed to assess liver damage quantitatively in chronic HF (CHF) with sound touch elastography (STE). A total of 150 subjects were enrolled, including HF with reduced ejection fraction (HFrEF) groups (left ventricular ejection fraction ≤40%, n = 45), HF with mildly reduced ejection fraction (HFmrEF) groups (left ventricular ejection fraction between 41% and 49%, n = 40), and right-sided HF (RHF) groups (n = 25); normal groups (n = 40). Liver stiffness measurement (LSM) was performed in all subjects by STE. The other hepatic parameters were also measured. The LSM was 5.4 ± 1.1 kPa in normal subjects and increased slightly to 5.9 ± 0.7 kPa in patients with HFmrEF. However, the HFrEF and RHF groups had significantly higher LSMs of 8.4 ± 2.0 kPa and 10.3 ± 2.7 kPa, respectively. The LSM of HFrEF was significantly higher than that of HFmrEF, whereas the increase in LSM in patients with RHF was significant relative to HFmrEF and HFrEF. In addition, the other parameters showed abnormal values in only RHF and HFrEF. In conclusion, STE is a useful clinical technique for the noninvasive evaluation of liver stiffness associated with CHF, which could help patients with CHF manage their treatment regimens.
BACKGROUND: PanNETs are a rare group of pancreatic tumors that display heterogeneous histopathological and clinical behavior. Nodal disease has been established as one of the strongest predictors of patient outcomes in PanNETs. Lack of accurate preoperative assessment of nodal disease is a major limitation in the management of these patients, in particular those with small (< 2 cm) low-grade tumors. The aim of the study was to evaluate the ability of radiomic features (RF) to preoperatively predict the presence of nodal disease in pancreatic neuroendocrine tumors (PanNETs).
PATIENTS AND METHODS: An institutional database was used to identify patients with nonfunctional PanNETs undergoing resection. Pancreas protocol computed tomography was obtained, manually segmented, and RF were extracted. These were analyzed using the minimum redundancy maximum relevance analysis for hierarchical feature selection. Youden index was used to identify the optimal cutoff for predicting nodal disease. A random forest prediction model was trained using RF and clinicopathological characteristics and validated internally.
RESULTS: Of the 320 patients included in the study, 92 (28.8%) had nodal disease based on histopathological assessment of the surgical specimen. A radiomic signature based on ten selected RF was developed. Clinicopathological characteristics predictive of nodal disease included tumor grade and size. Upon internal validation the combined radiomics and clinical feature model demonstrated adequate performance (AUC 0.80) in identifying nodal disease. The model accurately identified nodal disease in 85% of patients with small tumors (< 2 cm).
CONCLUSIONS: Non-invasive preoperative assessment of nodal disease using RF and clinicopathological characteristics is feasible.
PURPOSE:To easily produce delicious and high-quality food, highly active and stable medicine, etc., by using crystalline alpha-maltose as a dehydrating agent, incorporating the agent into water-contg. matter, and converting the agent into beta-maltose hydrate crystals. CONSTITUTION:In dehydrating water-contg. matter especially in reducing the water content of food, medicine, etc., contg. free water, crystalline alpha-maltose is incorporated into the water-contg. matter, about 5wt% water in the water- contg. matter is forcibly taken away by the crystalline alpha-maltose as the crystallization water of the beta-maltose hydrate crystal, and the water in the water-contg. matter is substantially reduced and removed. Furthermore, the beta-maltose hydrate crystal is not sticky and does not flow out. Moreover, the maltose itself is non-poisonous, harmless, and safe natural sweets, and hence the agent can be easily used in feed and medicine.
PROBLEM TO BE SOLVED: To obtain a new compound to be used as an active ingredient for medicinal compositions, esp. having production-controlling effect on tumor necrotic factors and vascularization inhibitory activity and/or aminopeptidase N inhibitory activity. SOLUTION: This new compound (salt) is shown by formula I (R is adamanthyl or 2,6-diisopropylphenyl; X is nitro, amino, cyano, trifluoromethyl, hydroxy, a halogen or lower alkyl; Y and Z are each O or S; (m) is 0-4; (n) is 0 or 1), e.g. N-(2,6-diisopropylphenyl)isoindoline. The compound of formula I is obtained by reaction between a compound of formula II and a compound of the formula R-NH2 (when Y is O and (n) is zero). The other objective medicinal composition containing this new composition is useful for treating such immunological diseases as graft rejection, rheumatic fever, Behcet's disease and aphthous ulcer, and for prophylaxis/treatment of inflammatory diseases and allergic diseases.
<P>PROBLEM TO BE SOLVED: To provide a new assay method of a substance for controlling migration outside of an Rev protein kernel.  <P>SOLUTION: A DNA originating from HIV is transfected to a cell, and the quantity of a structural protein p24 that manifests itself as a result is determined by an ELISA method, thus evaluating the inhibition activity of migration outside of a Rev kernel in a substance to be inspected. In this case, a cell sample having an inhibition rate of 0% and that having an inhibition rate of 100% are used contrastively, and both of them are compared, thus quantitatively evaluating the inhibition activity of migration outside of the Rev kernel of the substance to be inspected. And luciferases genes are transfected to each cell simultaneously with a DNA originated from HIV, a rough protein liquid extracted from each cell with the luciferases genes as a reference is diluted, and the amount of generation of p24 is measured in each weak diluted solution. A result for showing an improved quantity determination properties and reproducibility was obtained for the inhibition activity of transition outside of the Rev kernel of the substrate to be inspected by the assay method.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The T3 external hex implants available for this study will consist of lengths of 10mm, 11.5mm, 13mm, 15mm, 18mm and diameters of 4mm, 5mm, and 6mm. They have integrated platform switching (medialized implant/abutment junction). For study both configurations, T3 without nano-scale Discrete Crystalline Deposition (non DCD- surface treatment) and T3 with nano-scale Discrete Crystalline Deposition (with DCD- surface treatment), will be used.
Low dose aspirin is used for the primary and secondary prevention of cardiovascular thromboembolic events. As a non-selective inhibitor of cyclooxygenase, aspirin use results in irreversible COX-1 inhibition leading to impaired platelet aggregation. However, aspirin also inhibits COX-1 activity in the gastric mucosa by suppressing the synthesis of protective prostaglandins. In doing so, this creates a state of propensity for the development of aspirin-associated gastrointestinal ulcers and ulcer complications.

A high proportion of aspirin users also require concomitant use of anti-inflammatory medications for the treatment of pain and arthritis. However, evidence suggests that the risk of developing gastroduodenal ulcers and ulcer complications is significantly increased when aspirin is co-administered with other nonselective NSAIDs. In a previous study, concomitant aspirin (325 mg daily) in healthy subjects taking naproxen (500mg bid) was associated with endoscopic ulcer rates of 27.3% as compared to aspirin alone (7.6%). In a separate and independent trial of similar design, patients using 81 mg of aspirin in conjunction with daily naproxen also resulted in a higher incidence of gastric and duodenal ulcers than aspirin therapy alone. Beyond endoscopic ulcer rates, the risk of upper gastrointestinal hemorrhage has been reported to be substantially increased with concurrent administration of low-dose aspirin with nonselective NSAIDS. These data suggest that the gastrointestinal toxicity of combined aspirin with other NSAIDs may be more than additive.
1. A peptide capable of binding to ICE which peptide has in accordance with the List of sequences the amino acid sequence of SEQ ID NO:1, in which Xaa is Asp or Ala. 2. The peptide according to Claim 1, consisting essentially of the amino acid sequence of SEQ ID NO:2. 3. The peptide according to Claim 1, consisting essentially of the amino acid sequence of SEQ ID NO:3. 4. The peptide according to Claim 1, additionally comprising one or more amino acids at the N-terminal and/or C-terminal end and consisting of 20-40 amino acids. 5. The peptide according to Claim 1, consisting essentially of the amino acid sequence of SEQ ID NO:4. 6. The peptide according to Claim 1, consisting essentially of the amino acid sequence of SEQ ID NO:5. 7. Use of the peptide according to any of Claims 1-6, for treating diseases requiring ICE inhibition. 8. Use of the peptide according to any of Claims 1-6, as active source for the preparation of pharmaceutical compositions used in treating pathologies requiring ICE inhibition. 9. Use according to Claim 8, characterised by the fact that the pathology is selected from the group of autoimmune diseases. 10. Use according to Claim 8, characterised by the fact that the pathology is selected from the group consisting of lethal bacterial and viral infections. 11. Use according to Claim 8, characterised by the fact that the pathology is selected from the group consisting of inflammatory diseases. 12. Pharmaceutical composition used for prophylaxis, therapy or diagnostics of diseases requiring ICE inhibition, comprising peptide according to any of Claims 1-6 together with one or more pharmaceutically acceptable carriers and/or fillers. 13. Pharmaceutical composition according to Claim 12, characterised by the fact that the pathology is selected from the group of autoimmune diseases. 14. Pharmaceutical composition according to Claim 12, characterised by the fact that the pathology is selected from the group consisting of lethal bacterial and viral infections. 15. Pharmaceutical composition according to Claim 12, characterised by the fact that the pathology is selected from the group consisting of inflammatory diseases.
A live attenuated strain of Streptococcus pneumoniae comprising at least two genes or operons that have disrupted expression or encode for a protein with impaired function. The genes or operons are selected from fhs, piaA, proABC, spxB, Sp_1288 and Sp_1027. The strain can comprise an antibiotic resistance cassette. A further aspect of the invention is a pharmaceutical composition comprising the live attenuated strain of S. pneumoniae. The composition can comprise strains of different serotypes. The composition can be in a spray (e.g. nasal spray). The composition can prevent infection and enhance immunity. The strain or composition can prevent nasopharyngeal colonization of S. pneumoniae. The strain or composition can prevent infection, pneumonia, septicaemia, meningitis, COPD, bronchitis, sinusitis or otitis connected with S. pneumoniae. The S. pneumoniae infection can be of homologous or heterologous serotype to the strain. The strain or composition can be administered to the upper airway. The strain or composition can be administered intranasally, nasopharyngeally, to the oropharynx, subcutaneously, intradermally or intramuscularly. Another aspect of the invention is a live attenuated strain for preventing conditions associated with S. pneumoniae wherein at least one gene or operon selected from fhs, proABC, Sp_1288 or Sp_1027 is disrupted.